Esterified cellulose ethers of low viscosity
View Patent ↗Esterified cellulose ethers which comprise (i) aliphatic monovalent acyl groups or (ii) groups of the formula —C(O)—R—COOA, wherein R is a divalent aliphatic or aromatic hydrocarbon group and A is hydrogen or a cation, or (iii) a combination of aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOA, which have a viscosity of up to 2.33 mPa·s, measured as a 2.0 wt % solution of the esterified cellulose ether in 0.43 wt % aqueous NaOH at 20° C., and which have a viscosity of up to 13 mPao·s, measured as a 10 wt % solution of the esterified cellulose ether in acetone at 20° C. are useful for preparing solid dispersions comprising drugs.
1. A hydroxypropyl methyl cellulose acetate succinate (HPMCAS)
having a viscosity of up to 2.33 mPa·s, measured as a 2.0 wt % solution of the HPMCAS in 0.43 wt % aqueous NaOH at 20° C., and
having a viscosity of up to 13 mPa·s, measured as a 10 wt % solution of the HPMCAS in acetone at 20° C.
2. The HPMCAS of claim 1 having a viscosity of from 1.20 to 1.80 mPa·s, measured as a 2.0 wt % solution of the HPMCAS in 0.43 wt % aqueous NaOH at 20° C.
3. The HPMCAS of claim 1 having a viscosity of up to 10 mPa·s, measured as a 10 wt % solution of the HPMCAS in acetone at 20° C.
4. The HPMCAS of claim 3 having a viscosity of up to 3 mPa·s, measured as a 10 wt % solution of the HPMCAS in acetone at 20° C.
5. The HPMCAS of claim 1 having a weight average molecular weight of M w of from 90,000 to 350,000 Dalton.
6. The HPMCAS of claim 1 having a weight average molecular weight of M w of from 10,000 to 90,000 Dalton.
7. A composition comprising a liquid diluent and at least one HPMCAS of claim 1 .
8. The composition of claim 7 additionally comprising at least one active ingredient and optionally one or more adjuvants.
9. The composition of claim 7 comprising from 10 to 25 percent of at least one HPMCAS, from 70 to 89 percent of a liquid diluent, and from 1 to 15 percent of an active ingredient, based on the total weight of the composition.
10. A solid dispersion comprising at least one active ingredient and at least one HPMCAS of claim 1 .
11. The solid dispersion of claim 10 wherein the solid dispersion has been formulated into tablets, pills, granules, pellets, caplets, microparticles, fillings of capsules, or into a paste, cream, suspension or slurry.
12. A dosage form being coated with at least one HPMCAS of claim 1 .
13. A capsule shell comprising at least one HPMCAS of claim 1 .